Erasca to Present Early SEACRAFT-1 Phase 1 Data for Naporafenib and Trametinib in RAS Q61X Mutant Tumors at 36th EORTC-NCI-AACR Symposium

Erasca, Inc., a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, announced an oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib combined with trametinib (MEKINIST®) at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics. This symposium is being held from October 23-25 in Barcelona, Spain.

Naporafenib is a promising pan-RAF inhibitor with potential to be both first-in-class and best-in-class. The SEACRAFT-1 study is an open-label trial that examines the effects of naporafenib alongside trametinib in patients with locally advanced unresectable or metastatic solid tumor malignancies harboring RAS Q61X mutations. Dr. Elisa Fontana from the Sarah Cannon Research Institute in London, UK, will present the preliminary results on October 24, 2024, at 10:18 AM CEST in a session titled "Proffered Papers: Advancing patient care through novel clinical trials."

Erasca will also host a virtual investor event to discuss their research and development progress on naporafenib and their broader RAS-targeting initiatives. This event will take place on October 24, 2024, at 8:30 AM ET, coinciding with the ENA Symposium. The event will include a live question-and-answer session following the formal presentation.

Erasca is dedicated to eradicating cancer by focusing on the RAS/MAPK pathway, a critical signaling pathway involved in cancer development. The company was co-founded by pioneers in precision oncology and RAS targeting, aiming to create innovative therapies and combination regimens to fully inhibit the RAS/MAPK pathway for cancer treatment. Erasca has developed one of the most extensive RAS/MAPK pathway-focused pipelines in the industry. The company's team and scientific advisory board, which includes leading experts in the RAS/MAPK pathway, are uniquely positioned to achieve their mission of eliminating cancer.